News
LGND
69.99
-3.99%
-2.91
Barclays Maintains Overweight on Ligand Pharmaceuticals, Lowers Price Target to $120
Benzinga · 11/21 12:31
Sermonix Pharmaceuticals Announces Four Abstracts Accepted for Presentation at 2022 San Antonio Breast Cancer Symposium
COLUMBUS, Ohio, Nov. 17, 2022 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative targeted therapeutics to specifically treat ESR1-mutated metastatic breast and gynecological cancers, today an...
GlobeNewswire · 11/17 14:00
Ligand to Hold Investor and Analyst Day on December 13
SAN DIEGO, November 16, 2022--Ligand to Hold Investor and Analyst Day on December 13
Business Wire · 11/16 13:00
Insider Sell: Ligand Pharmaceuticals
Insider Sell: Ligand Pharmaceuticals
MT Newswires · 11/10 16:59
Ligand rises 16% as company sees 2022 earnings above estimates
Seekingalpha · 11/08 19:03
BRIEF-Ligand Pharmaceuticals Says Quarterly Diluted Net Income Per Share $0.02
Reuters · 11/07 21:35
BRIEF-Ligand Pharmaceuticals Inc Expects FY22 Total Revenue Between $184 Mln To $189 Mln
Reuters · 11/07 21:28
Ligand Pharmaceuticals Non-GAAP EPS of $0.41 misses by $0.02, revenue of $66.09M beats by $27.76M
Seekingalpha · 11/07 21:25
Ligand Pharmaceuticals Q3 EPS $1.31 Down From $1.58 YoY, Sales $66.09M Up From $64.83M YoY
Benzinga · 11/07 21:03
-- Earnings Flash (LGND) LIGAND PHARMACEUTICALS INCORPORATED Reports Q3 Revenue $66.1M, vs. Street Est of $38.3M
-- Earnings Flash (LGND) LIGAND PHARMACEUTICALS INCORPORATED Reports Q3 Revenue $66.1M, vs. Street Est of $38.3M
MT Newswires · 11/07 16:13
-- Earnings Flash (LGND) LIGAND PHARMACEUTICALS INCORPORATED Posts Q3 EPS $0.41, vs. Street Est of $0.43
-- Earnings Flash (LGND) LIGAND PHARMACEUTICALS INCORPORATED Posts Q3 EPS $0.41, vs. Street Est of $0.43
MT Newswires · 11/07 16:08
Earnings Scheduled For November 7, 2022
Benzinga · 11/07 08:59
Ligand Pharmaceuticals Q3 2022 Earnings Preview
Seekingalpha · 11/06 20:35
Earnings Outlook For Ligand Pharmaceuticals
Benzinga · 11/04 17:09
Sonoma, Arcturus top healthcare gainers; TFF Pharmaceuticals, Semler among losers
Seekingalpha · 11/02 14:03
Ligand Pharma jumps 32% as OmniAb completes spinoff and merger
Seekingalpha · 11/02 13:27
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Benzinga · 11/02 12:20
Provention Bio's Second Try, Apellis's Eye Disorder Drug Review, 3 Adcom Verdicts And More: November's Key PDUFA Catalysts Biotech Investors Must Know
Benzinga · 11/01 20:01
Heska (HSKA) Reports Next Week: Wall Street Expects Earnings Growth
Heska (HSKA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks · 11/01 14:01
More
Webull provides a variety of real-time LGND stock news. You can receive the latest news about Ligand Pharma through multiple platforms. This information may help you make smarter investment decisions.
About LGND
Ligand Pharmaceuticals Incorporated is a biopharmaceutical company. It is focused on developing or acquiring technologies that help pharmaceutical companies discover and develop medicines. It has partnerships and license agreements with approximately 140 pharmaceutical and biotechnology companies and 400 programs are in various stages of commercialization, development, or research and are fully funded by its collaboration partners and licensees. The Company's OmniAb business segment is focused on enabling the discovery of therapeutic candidates for its partners by pairing antibody repertoires generated from its proprietary transgenic animals with its OmniAb business platform screening tools. The Company's Ligand core business segment is a biopharmaceutical business focused on developing or acquiring technologies that help pharmaceutical companies deliver and develop medicines. The OmniAb platform creates and screens diverse antibody pools and is designed to identify optimal antibodies.